USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
Gull Global Limited and Dr. Myron W. Wentz report beneficial ownership of 7,408,345 shares of USANA Health Sciences common stock, representing 40.1% of the outstanding shares, based on 18,456,935 shares outstanding as of March 13, 2026. The shares are held directly by Gull Global, with Dr. Wentz deemed a beneficial owner through a Bahamas-based trust structure he controls.
The filing describes a long history of transactions, including a terminated 2008 tender offer, open-market sales, option and stock-settled stock appreciation right exercises, and charitable gifts of shares. Since the 2008 offer termination, the reporting persons have held the position for investment purposes while periodically selling shares for liquidity and making donations, and report no transactions in the 60 days before this amendment.
USANA Health Sciences Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock and beneficial ownership of 0% following an internal realignment effective January 12, 2026. The filing explains certain Vanguard subsidiaries now report ownership separately under SEC Release No. 34-39538.
USANA Health Sciences director Gilbert A. Fuller sold shares in an open-market transaction. He sold 1,058 shares of common stock at a price of $17.00 per share. After this sale, the filing shows he directly owns 0 shares of USANA common stock.
USANA Health Sciences reports a diversified health and wellness business built around nutritional supplements, functional foods and personal care products sold globally. In 2025, the company generated $925 million in net sales and ended the year with about 387,000 active core nutritional Customers.
Mainland China is the largest market, contributing roughly 41.3% of net sales, with about 75.7% of consolidated net sales generated outside the United States. The business is now organized into two reportable segments: core nutritional and Hiya direct-to-consumer, complemented by smaller brands Rise and Oola.
USANA acquired a 78.85% interest in Hiya in December 2024, adding a subscription-based children’s wellness brand and accelerating its shift to an omni‑channel model that includes direct selling, direct‑to‑consumer, third‑party marketplaces and retail. As of January 3, 2026, Hiya had approximately 181,700 active Monthly Subscribers.
The company highlights ongoing R&D investment of $10.7 million in 2025, in‑house manufacturing for about 56% of products, and a revamped Brand Partner Compensation Plan launched in 2025 to enhance earning opportunities and customer growth. Management emphasizes growth initiatives in China, India, and new international markets, while expanding Hiya and Rise into online marketplaces and retail.
USANA also outlines extensive regulatory, legal, and compliance risks tied to dietary supplement rules, direct selling scrutiny by the FTC, and evolving direct selling and health‑product regulation in China, where operations run through its BabyCare subsidiary.
USANA Health Sciences' chief information officer, Peter Benedict, sold 4,553 shares of company common stock in an open-market transaction. The shares were sold at a weighted average price of $19.3848 per share, with individual trade prices ranging from $19.29 to $19.415. Following this sale, Benedict reported owning no shares of USANA common stock directly.
USNA filed a Form 144 reporting proposed sales of its common stock by insiders and related parties. The filing lists proposed sales of restricted common stock dated 02/06/2026 (653 shares), 02/07/2026 (412 shares), 02/08/2026 (756 shares) and 02/27/2026 (2,732 shares).
The filing also records a sale by Peter G. Benedict of 2,673 common shares on 12/10/2025 for $56,000.95.
USANA Health Sciences' Chief Operating Officer Walter Noot reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised or converted 7,422 restricted stock units, each representing a right to receive one share of USANA common stock.
This conversion resulted in the acquisition of 7,422 shares of common stock at no exercise price, and a remaining balance of 75,130 restricted stock units held directly after the transaction. Following the stock acquisition, 3,144 common shares were disposed of at $21.52 per share to satisfy tax obligations by delivering shares.
After these transactions, Noot directly owned 9,256 shares of USANA common stock. Footnotes state that the restricted stock units vest 25% on the anniversary of February 27, 2025, linking these movements to the vesting schedule of prior equity awards.
USANA Health Sciences chief commercial officer Brent Neidig reported equity award activity involving restricted stock units and common shares. He exercised 6,747 restricted stock units, each representing a right to receive one USANA common share, and acquired 6,747 common shares at no cash price. On the same date, 2,993 common shares were withheld at $21.52 per share to satisfy tax obligations related to the award, leaving him with 7,513 directly owned common shares and 67,447 restricted stock units. The restricted stock units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences Chief People Officer Paul A. Jones reported equity compensation activity involving restricted stock units and common shares. On February 27, 4,596 restricted stock units were exercised and converted into 4,596 shares of common stock at a price of $0.00 per share. A separate transaction on the same date disposed of 1,349 common shares at $21.52 per share to cover tax obligations through share withholding. After these transactions, Jones directly held 46,611 restricted stock units and 12,374 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences' chief financial officer IIEKKING G DOUG reported equity award activity. On February 27, 2026, he exercised 7,469 Restricted Stock Units, converting them into the same number of common shares at $0.00 per share. Following this conversion, his directly held common stock position was 10,391 shares before a separate tax transaction. On the same date, 5,031 common shares were disposed of at $21.52 per share to cover tax obligations, leaving him with 5,360 common shares held directly. Footnotes state each restricted stock unit represents one share of common stock and that these units vest 25% on the anniversary of February 27, 2025.